Dyax Announces Expansion Of Phase 1b Clinical Trial Evaluating DX-2930

(RTTNews) - Dyax Corp. (DYAX) Monday announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts.

Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema or HAE attacks.

The ongoing Phase 1b clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to assess the safety, tolerability and pharmacokinetics of DX-2930 in HAE patients.

As of October 31, 21 subjects were enrolled and completed dosing in three ascending dose cohorts of DX-2930 or placebo.

In light of faster than expected enrollment rates, Dyax has decided to take the opportunity to further characterize DX-2930 by adding two additional cohorts.

Subjects will continue to be randomized to active drug or placebo in a 2:1 ratio and the dosing regimen will remain unchanged.